We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
Read MoreHide Full Article
Key Takeaways
TEM launched xM liquid biopsy to monitor ICI therapy response in solid tumors.
Tempus AI introduced Loop, an AI platform combining RWD and CRISPR screens.
Development of xH signals TEM's move into WGS to guide hematologic cancer treatment choice.
Tempus AI (TEM - Free Report) continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay to detect molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors. It is currently available for research use only, with clinical availability expected later this year. In May, TEM launched its Fuses program to generate valuable insights for both patient care and research. Fuses will accelerate the company’s comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. In April, Tempus AI announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is its proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR screens, all leveraging AI to rapidly uncover insights for preclinical therapeutic development.
In January, Tempus AI launched olivia, an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. The company also launched an FDA-approved, next-generation sequencing (NGS)-based in vitro diagnostic device, xT CDx. xT CDx is a 648-gene NGS test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
In terms of product in the pipeline, Tempus AI is developing its first whole-genome sequencing test, xH. This test marks the company’s first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with the detection of all clinically relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.
Tempus AI’s Peers Making Significant Strides With Product Innovation
Veracyte (VCYT - Free Report) significantly advanced its product pipeline, positioning itself as a strong player in the precision diagnostics and AI-driven testing space. The company launched its Decipher Prostate metastatic test in a limited capacity in April, with a full rollout planned for June. This launch expands Decipher’s reach to the entire spectrum of prostate cancer, providing actionable insights for metastatic patients to guide treatment decisions and avoid unnecessary chemotherapy. Additionally, Veracyte plans to launch an updated version of its Afirma test in summer 2025, incorporating its v2 transcriptome. It also aims to launch the Prosigna lab-developed test for breast cancer in the United States in 2026. Finally, Veracyte is progressing toward the launch of its Percepta Nasal Swab test for lung cancer risk assessment.
Myriad Genetics (MYGN - Free Report) invests in the development of new innovative testing products and enhances its existing portfolio of testing products. Last year, it launched the new Prequel Prenatal Screen, which delivers critical insights at eight weeks of gestational age as compared to 10 or 12 weeks. Myriad Genetics introduced the Foresight Carrier Screening test with a new Universal Plus Panel featuring an expanded panel of genes and more efficient workflows. Additionally, Myriad Genetics announced early access to the FirstGene — a combined carrier screening and noninvasive prenatal testing assay — and its first AI-enabled Prolaris test to support clinical divisions at the time of biopsy in partnership with OMIC.
TEM’s Price Performance & Expensive Valuation
In the past year, Tempus AI shares have surged 83.6%, outperforming the industry’s 38% growth and the S&P 500 composite’s 12.3% improvement.
Image Source: Zacks Investment Research
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.50X compared with the industry average of 5.88X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
Earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture.
Image Source: Zacks Investment Research
TEM’s Zacks Rank
TEM stock currently carries a Zacks Rank #4 (Sell).
Image: Bigstock
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
Key Takeaways
Tempus AI (TEM - Free Report) continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay to detect molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors. It is currently available for research use only, with clinical availability expected later this year. In May, TEM launched its Fuses program to generate valuable insights for both patient care and research. Fuses will accelerate the company’s comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. In April, Tempus AI announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is its proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR screens, all leveraging AI to rapidly uncover insights for preclinical therapeutic development.
In January, Tempus AI launched olivia, an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. The company also launched an FDA-approved, next-generation sequencing (NGS)-based in vitro diagnostic device, xT CDx. xT CDx is a 648-gene NGS test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
In terms of product in the pipeline, Tempus AI is developing its first whole-genome sequencing test, xH. This test marks the company’s first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with the detection of all clinically relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.
Tempus AI’s Peers Making Significant Strides With Product Innovation
Veracyte (VCYT - Free Report) significantly advanced its product pipeline, positioning itself as a strong player in the precision diagnostics and AI-driven testing space. The company launched its Decipher Prostate metastatic test in a limited capacity in April, with a full rollout planned for June. This launch expands Decipher’s reach to the entire spectrum of prostate cancer, providing actionable insights for metastatic patients to guide treatment decisions and avoid unnecessary chemotherapy. Additionally, Veracyte plans to launch an updated version of its Afirma test in summer 2025, incorporating its v2 transcriptome. It also aims to launch the Prosigna lab-developed test for breast cancer in the United States in 2026. Finally, Veracyte is progressing toward the launch of its Percepta Nasal Swab test for lung cancer risk assessment.
Myriad Genetics (MYGN - Free Report) invests in the development of new innovative testing products and enhances its existing portfolio of testing products. Last year, it launched the new Prequel Prenatal Screen, which delivers critical insights at eight weeks of gestational age as compared to 10 or 12 weeks. Myriad Genetics introduced the Foresight Carrier Screening test with a new Universal Plus Panel featuring an expanded panel of genes and more efficient workflows. Additionally, Myriad Genetics announced early access to the FirstGene — a combined carrier screening and noninvasive prenatal testing assay — and its first AI-enabled Prolaris test to support clinical divisions at the time of biopsy in partnership with OMIC.
TEM’s Price Performance & Expensive Valuation
In the past year, Tempus AI shares have surged 83.6%, outperforming the industry’s 38% growth and the S&P 500 composite’s 12.3% improvement.
Image Source: Zacks Investment Research
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.50X compared with the industry average of 5.88X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
Earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture.
Image Source: Zacks Investment Research
TEM’s Zacks Rank
TEM stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.